PLGA from PolySciTech used in development of anti-viral delivery system for treatment of respiratory diseases
The pandemic highlighted the need to provide for reliable treatment of respiratory diseases. One way to treat a viral respiratory disease is to deliver a high dose of antiviral agent in a localized manner to the respiratory tissue. This is optimally achieved with an inhaled formulation which can deliver drugs to the affect lung and throat tissues quickly. Researchers at University of Texas at Arlington and University of Southern Mississippi used PLGA (catalog # AP040) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop a nanoparticle drug delivery system for inhaled delivery of antiviral Remdesivir. This antiviral agent can be used as a therapeutic option for respiratory diseases in the future. Read more: Chintapula, Uday, Shazeed-Ul Karim, Priyanka Raghunathan Iyer, Haritha Asokan-Sheeja, Biswas Neupane, Farzana Nazneen, He Dong, Fengwei Bai, and Kytai T. Nguyen. "A novel nanocomposite drug delivery system for SARS-CoV-2 infections." (2024). www.researchga...
“To develop an inhalable drug delivery system, we synthesized poly (lactic-co-glycolic acid) nanoparticles with Remdesivir (RDV NPs) as an antiviral agent against SARS-CoV-2 replication and formulated Remdesivir-loaded nanocomposites (RDV NCs) via coating of RDV NPs with novel supramolecular cellpenetrating peptide nanofibers (NFs) to enhance cellular uptake and intracellular drug delivery. RDV NPs and RDV NCs were characterized using variou techniques, including Transmission Electron Microscopy (TEM), Dynamic Light Scattering (DLS), and fluorescent microscopy. The cytotoxicity of RDV NCs was assessed in Vero E6 cells and primary human lung epithelial cells, with no significant cytotoxicity observed up to 1000 mgmL−1 and 48 h. RDV NCs were spherically shaped with a size range of 200300 nm and a zeta potential of ∼+31 mV as well as indicating the presence of coated nanofibers. Reverse Transcription-quantitative Polymerase Chain Reaction (RT-qPCR), immunofluorescence and plaque assays of SARS-CoV-2 infected Vero E6 treated with RDV NCs showed significantly higher antiviral activities compared to those of free drug and uncoated RDV NPs. RDV NCs exhibited high antiviral activity against SARS-CoV-2, and the nanocomposite platform has the potential to be developed into an inhalable drug delivery system for other viral infections in the lungs.”
PLGA AP040: akinainc.com/p...
NEW: Corbion Purasorb® Polymers: akinainc.com/p...
NEW: Ashland-TM products: akinainc.com/p...
29 сен 2024
